The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Virus-like particles—universal molecular toolboxes
Open accessAbstract
Virus-like particles (VLPs) are highly organised spheres that self-assemble from virus-derived structural antigens. These stable and versatile subviral particles possess excellent adjuvant properties capable of inducing innate and cognate immune responses. Commercialised VLP-based vaccines have been successful in protecting humans from hepatitis B virus (HBV) and human papillomavirus (HPV) infection and are currently explored for their potential to combat other infectious diseases and cancer. Much insight into VLP-mediated immune stimulation and optimised VLP design has been gained from human immunodeficiency virus (HIV)-derived VLPs presenting promising components of current AIDS vaccine approaches. Owing to their unique features, VLPs and virosomes, the in vitro-reconstituted VLP counterparts, have recently gained ground in the field of nanobiotechnology as organic templates for the development of new biomaterials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes
Nam, K. T., Kim, D.-W., Yoo, P. J., Chiang, C.-Y., Meethong, N., Hammond, P. T., Chiang, Y.-M., & Belcher, A. M. (2006) · Science · doi:10.1126/science.1122716 · Cited by 1,855
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
Virus-Based Toolkit for the Directed Synthesis of Magnetic and Semiconducting Nanowires
Mao, C., Solis, D. J., Reiss, B. D., Kottmann, S. T., Sweeney, R. Y., Hayhurst, A., Georgiou, G., Iverson, B., & Belcher, A. M. (2004) · Science · doi:10.1126/science.1092740 · Cited by 967
Gheysen, D., Jacobs, E., de Foresta, F., Thiriart, C., Francotte, M., Thines, D., & De Wilde, M. (1989) · Cell · doi:10.1016/0092-8674(89)90873-8 · Cited by 747
Human hepatitis B vaccine from recombinant yeast
McAleer, W. J., Buynak, E. B., Maigetter, R. Z., Wampler, D. E., Miller, W. J., & Hilleman, M. R. (1984) · Nature · doi:10.1038/307178a0 · Cited by 739
Virus-like particles: Passport to immune recognition
Grgacic, E. V. L., & Anderson, D. A. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.018 · Cited by 582
Viral vectors for the expression of proteins in plants
Gleba, Y., Klimyuk, V., & Marillonnet, S. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.03.002 · Cited by 435
Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
Felnerova, D., Viret, J.-F., Glück, R., & Moser, C. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.10.005 · Cited by 296
Self‐Assembly and Cross‐Linking of Bionanoparticles at Liquid–Liquid Interfaces
Russell, J. T., Lin, Y., Böker, A., Su, L., Carl, P., Zettl, H., He, J., Sill, K., Tangirala, R., Emrick, T., et al. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462653 · Cited by 269
Abe, T., Takahashi, H., Hamazaki, H., Miyano-Kurosaki, N., Matsuura, Y., & Takaku, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1133 · Cited by 229
Abe, T., Hemmi, H., Miyamoto, H., Moriishi, K., Tamura, S., Takaku, H., Akira, S., & Matsuura, Y. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2847-2858.2005 · Cited by 226
Virus-like particles as vaccines and vessels for the delivery of small molecules
Garcea, R. L., & Gissmann, L. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.10.002 · Cited by 187
Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN
Hervas-Stubbs, S., Rueda, P., Lopez, L., & Leclerc, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2361 · Cited by 175
Deml, L., Speth, C., Dierich, M. P., Wolf, H. J., & Wagner, R. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.06.028 · Cited by 147
Self-citationBuonaguro, L., Tornesello, M. L., Tagliamonte, M., Gallo, R. C., Wang, L., Kamin‐Lewis, R., Abdelwahab, S. F., Lewis, G. K., & Buonaguro, F. M. (2006) · Journal of Virology · doi:10.1128/jvi.00050-06 · Cited by 137
Swenson, D. L., Warfield, K. L., Negley, D. L., Schmaljohn, A. L., Aman, M. J., & Bavari, S. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.070 · Cited by 133
Paliard, X., Liu, Y., Wagner, R., Wolf, H. J., Baenziger, J., & Walker, C. M. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/088922200309368 · Cited by 121
Self-citationVirus-like particles as HIV-1 vaccines
Doan, L. X., Li, M., Chen, C., & Yao, Q. C. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.449 · Cited by 116
Ye, L., Lin, J., Sun, Y., Bennouna, S., Lo, M. K., Wu, Q., Bu, Z., Pulendran, B., Compans, R. W., & Yang, C. (2006) · Virology · doi:10.1016/j.virol.2006.03.021 · Cited by 104
Virus-like particles: Designing an effective AIDS vaccine
Young, K. R., McBurney, S. P., Karkhanis, L. U., & Ross, T. M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.024 · Cited by 100
Skountzou, I., Quan, F., Gangadhara, S., Ye, L., Vzorov, A. N., Selvaraj, P., Jacob, J., Compans, R. W., & Kang, S. (2006) · Journal of Virology · doi:10.1128/jvi.01692-06 · Cited by 83
Peacey, M., Wilson, S., Baird, M. A., & Ward, V. K. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21518 · Cited by 82
Tsunetsugu‐Yokota, Y., Morikawa, Y., Isogai, M., Kawana‐Tachikawa, A., Odawara, T., Nakamura, T., Grassi, M. F. R., Autran, B., & Iwamoto, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10250-10259.2003 · Cited by 82
Schauber, C., Tuerk, M., Pacheco, C. D., Escarpe, P., & Veres, G. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302170 · Cited by 79
Liu, X., Siegrist, S., Amacker, M., et al. (2006) · ACS Chemical Biology · doi:10.1021/cb600086b · Cited by 73
Wagner, R., Fließbach, H., Wanner, G., Motz, M., Niedrig, M., Deby, G., von Brunn, A., & Wolf, H. J. (1992) · Archives of Virology · doi:10.1007/bf01309579 · Cited by 70
Self-citationLu, X., Chen, Y., Bai, B., Hu, H., Tao, L., Yang, J., Chen, J., Chen, Z., Hú, Z., & Wang, H. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02676.x · Cited by 63
Influenza virosomes as an efficient system for adjuvanted vaccine delivery
Glück, R., Moser, C., & Metcalfe, I. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1139 · Cited by 63
Bellier, B., Dalba, C., Clerc, B., Desjardins, D., Drury, R., Cosset, F., Collins, M. K., & Klatzmann, D. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.034 · Cited by 62
Targeting her-2/neu with antirat Neu virosomes for cancer therapy.
Waelti, E. R., Wegmann, N., Schwaninger, R., Wetterwald, A., Wingenfeld, C., Rothen‐Rutishauser, B., & Gimmi, C. D. (2002) · PubMed · Cited by 56
McBurney, S. P., Young, K. R., & Ross, T. M. (2006) · Virology · doi:10.1016/j.virol.2006.08.032 · Cited by 56
Kuate, S., Stahl‐Hennig, C., Stoiber, H., Nchinda, G., Floto, A., Franz, M., Sauermann, U., Bredl, S., Deml, L., Ignatius, R., et al. (2006) · Virology · doi:10.1016/j.virol.2006.03.009 · Cited by 46
Self-citationOkitsu, S. L., Kienzl, U., Moehle, K., Silvie, O., Peduzzi, E., Mueller, M. S., Sauerwein, R. W., Matile, H., Zurbriggen, R., Mazier, D., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.04.008 · Cited by 41
Marsac, D., Loirat, D., Petit, C., Schwartz, O., & Michel, M.-L. (2002) · Journal of Virology · doi:10.1128/jvi.76.15.7544-7553.2002 · Cited by 39
Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells
Angel, J., Chaperot, L., Molens, J., Mezin, P., Amacker, M., Zurbriggen, R., Grichine, A., & Plumas, J. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.101 · Cited by 39
Clinical applications of virosomes in cancer immunotherapy
Adamina, M., Güller, U., Bracci, L., Heberer, M., Spagnoli, G. C., & Schumacher, R. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1113 · Cited by 23
Ted Slavin's Blood and the Development of HBV Vaccine
(1985) · New England Journal of Medicine · doi:10.1056/nejm198501173120322 · Cited by 13 · cited 1×
“Since HBsAgbased particles were first discovered in blood samples of hepatitis B patients and were soon developed into a potent vaccine against the cognate virus infection [2] , subviral particles have rapidly found their way into modern concepts of vaccine design.”
Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes
Westerfeld, N., Pluschke, G., & Zurbriggen, R. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0684-0 · Cited by 9
Tan, P., Xue, S., Wei, B. K., et al. (2007) · Molecular Medicine · doi:10.2119/2006-00052.tan · Cited by 7
Cited by
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Akahata, W., Yang, Z.-Y., Andersen, H., Sun, S., Holdaway, H. A., Kong, W.-P., Lewis, M. G., Higgs, S., Rossmann, M. G., Rao, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2105 · Cited by 515
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Hong, S., Zhang, Z., Liu, H., Tian, M., Zhu, X., Zhang, Z., Wang, W., Zhou, X., Zhang, F., Ge, Q., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.012 · Cited by 296
The Art of Engineering Viral Nanoparticles
Pokorski, J. K., & Steinmetz, N. F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100225y · Cited by 266
Metadata
- Authors
- Ludwig, C., & Wagner, R.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 18
- Issue
- 6
- Pages
- 537-545
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2026180733
- Cited by
- 303
- References
- 40
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.